Navigation Links
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
Date:6/30/2008

Company's End-of-Phase II Meeting with FDA Set for Sept. 29

LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to meeting the primary endpoint of headache pain relief at two hours, the company's lead AMPA/kainate-type glutamate receptor antagonist, tezampanel, demonstrated improvement on important secondary endpoints in a 306-patient Phase IIb clinical trial in acute migraine headache. Specifically, tezampanel demonstrated improvement in the following secondary endpoints: sustained headache response, absence of nausea or vomiting, absence of phonophobia and absence of photophobia.

"This is our second positive study in acute migraine with tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics, who presented the data. "In both studies, we have shown improvement in all of the endpoints that the FDA has indicated will be required for the drug's approval. Earlier this year we conducted a clinical guidance call with the FDA in which the agency said it has no objection with us moving forward with a Phase III study of the 40 mg dose of tezampanel. We have scheduled an end-of-Phase II meeting to discuss the entire Phase III program with the agency on Sept. 29."

In the Phase IIb clinical trial, tezampanel was well tolerated with no reports of serious or medically important adverse events. At the 40 mg dose, the most commonly reported adverse events compared to placebo were injection site pain (5.1 percent vs. 20 percent), injection site burning (3.8 percent vs. 6.7 percent), dizziness (6.4 percent vs. 5.3 percen
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
7. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
8. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
9. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... BCR-ABL That Cause Resistance to Current ... CML and ALL ... ) today reported preliminary phase 1 data from an ongoing,trial of ... lymphocytic leukemia (Ph+ALL) who,are resistant to or intolerant of the approved ...
... Also Experienced Improved Physical Functioning, INDIANAPOLIS, June ... pain of the knee treated with 60 mg ... significant pain,reduction. Patients taking duloxetine reported significant pain ... treatment that lasted,throughout the 13-week trial.(1) Results from ...
Cached Medicine Technology:Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 2Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 3Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 4Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 3Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 4Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 5
(Date:7/11/2014)... Emily Johnson, owner of the Portland Fit Body ... boot camp has held two charity workout events and is ... 26th, from 7:15 - 8:30 at Col Summers City Park, SE ... camp session raised $510 for Medical Teams International. Their second workout ... a Dream. On July 26th, Johnson and Portland Fit Body ...
(Date:7/11/2014)... 2014 As reported by Forbes in ... Are Genetics To Blame (6/30), Indino Downey has reportedly ... paraphernalia to smoke it with. His father, well-known actor ... son inherited from him may have something to do ... news during the 1980s and 1990s for substance abuse ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 ... today announces that he uses mini and full mouth ... offer the defining feature that distinguishes dental implants from ... in addition to the crowns. This alone prevents the ... also offer advantages related to comfort, appearance and ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... For breast cancer patients, the era of personalized medicine ... advances by USC Stem Cell researcher Min Yu and ... , In a July 11 study in Science ... breast cancer cells circulating through the blood streams of ... the "seeds" of metastasis, which travel to and establish ...
Breaking Medicine News(10 mins):Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Researchers Assess New Way to Boost Polio Immunity 2
... by the Canadian Association for Adolescent Health has found that ... are ignorant about important sex information.// ,The survey ... in casual sex and a half-million sexually active teens aged ... of teens claimed to have some knowledge about sex, but ...
... The infant formula Gentlease is being recalled from the market ... of metal particles in some cans. // So this brand ... makers of Gentlease powdered infant formula, Mead Johnson Nutritionals of ... batch number BMJ19 printed on the bottom of the cans. ...
... that swimming helps immensely the children to stay hale ... ,Researches conducted over six years at the Jigalong, ... examined the impact on children's health where swimming pools ... Institute for Child Health Research study found that at ...
... can do more than affecting just your gums. It ... premature delivery. // The following is the conclusion arrived ... York. ,Participants at the conference highlighted the ... association with gum disease. They further reflected the need ...
... level of which is strongly suggestive of prostate cancer in ... early signs of prostate cancer, // if any. A new ... needed for establishment of prostate cancer diagnosis in young men ... researchers from Duke University Medical Center analyzed more than 12,000 ...
... who is the principle investigator said that the new technique ... to discover molecules that can enhance or block different kinds ... succeeded in growing mature taste receptor cells outside the body. ... for a prolonged period of time. This is a break ...
Cached Medicine News:Health News:Unhealthy Gums Increase Risk Of Premature Delivery 2Health News:Functional Taste Cells Cultured In Vitro 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: